Literature DB >> 16206733

Treatment strategies for high-risk medulloblastoma and supratentorial primitive neuroectodermal tumors. Review of the literature.

Regina I Jakacki1.   

Abstract

Primitive neuroectodermal tumors (PNETs) are malignant tumors with a high propensity to disseminate throughout the cerebrospinal fluid. Current treatment guidelines are largely determined by clinically based prognostic factors, the most important of which are tumor location and the extent of tumor spread. Although the cure rate for high-risk PNETs has improved, the irreversible sequelae of craniospinal axis radiation treatment in patients who survive have motivated researchers to investigate more fully which patients can safely receive less treatment. The author reviews the literature, describes currently available treatment options for patients with high-risk PNETs, and discusses strategies aimed at improving outcome and refining prognosis that are currently being explored.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16206733     DOI: 10.3171/ped.2005.102.1.0044

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  13 in total

Review 1.  Medulloblastoma: therapy and biologic considerations.

Authors:  Timothy R Gershon; Orren J Becher
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

Review 2.  Emerging treatments and gene expression profiling in high-risk medulloblastoma.

Authors:  Iacopo Sardi; Duccio Cavalieri; Maura Massimino
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 3.  Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.

Authors:  Daniel M Green; Larry E Kun; Katherine K Matthay; Anna T Meadows; William H Meyer; Paul A Meyers; Sheri L Spunt; Leslie L Robison; Melissa M Hudson
Journal:  Pediatr Blood Cancer       Date:  2013-02-15       Impact factor: 3.167

4.  Extracellular matrix metalloproteinase inducer is a negative prognostic factor of pediatric medulloblastoma.

Authors:  Tongwei Chu; Xiaoyang Chen; Jie Yu; Jianwen Xiao; Zhou Fu
Journal:  Pathol Oncol Res       Date:  2011-03-31       Impact factor: 3.201

Review 5.  The molecular classification of medulloblastoma: driving the next generation clinical trials.

Authors:  Sarah E S Leary; James M Olson
Journal:  Curr Opin Pediatr       Date:  2012-02       Impact factor: 2.856

6.  Combination chemotherapy with ifosfamide, cisplatin, and etoposide for medulloblastoma: single-institute experience and differences in efficacy for subgroups of medulloblastoma.

Authors:  Ryuta Saito; Toshihiro Kumabe; Yukihiko Sonoda; Masayuki Kanamori; Yoji Yamashita; Mika Watanabe; Teiji Tominaga
Journal:  Childs Nerv Syst       Date:  2011-05-18       Impact factor: 1.475

7.  Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026).

Authors:  Sarah E S Leary; Lindsay Kilburn; J Russell Geyer; Mehmet Kocak; Jie Huang; Kyle S Smith; Jennifer Hadley; Ralph Ermoian; Tobey J MacDonald; Stewart Goldman; Peter Phillips; Tina Young Poussaint; James M Olson; David W Ellison; Ira J Dunkel; Maryam Fouladi; Arzu Onar-Thomas; Paul A Northcott
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

8.  REST is a novel prognostic factor and therapeutic target for medulloblastoma.

Authors:  Pete Taylor; Jason Fangusaro; Veena Rajaram; Stewart Goldman; Irene B Helenowski; Tobey MacDonald; Martin Hasselblatt; Lars Riedemann; Alvaro Laureano; Laurence Cooper; Vidya Gopalakrishnan
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

9.  Cognitive Sparing during the Administration of Whole Brain Radiotherapy and Prophylactic Cranial Irradiation: Current Concepts and Approaches.

Authors:  James C Marsh; Benjamin T Gielda; Arnold M Herskovic; Ross A Abrams
Journal:  J Oncol       Date:  2010-06-27       Impact factor: 4.375

10.  Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines.

Authors:  Ronald J Bernardi; Amanda R Lowery; Patrick A Thompson; Susan M Blaney; Jennifer L West
Journal:  J Neurooncol       Date:  2007-09-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.